CLAIMS:

1. (Amended) A peptide which comprises an analogue of the carboxyl-terminal sequence of a growth hormone, said carboxyl-terminal sequence containing amino acid residues 177-191 of human growth hormone:
Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe,
or a corresponding sequence of a non-human mammalian growth hormone; wherein in said analogue
(i) amino acids at positions 182 and 189 of hGH are joined by a bond to promote a cyclic conformation; and/or
(ii) amino acids at positions 183 and 186 of hGH are joined by a salt bridge or a covalent bond;
or an organic or inorganic acid addition salt thereof.

2. (Cancelled).

3. (Cancelled).

4. (Cancelled).

5. (Cancelled).

6. (Cancelled).

7. (Amended) A peptide according to claim 1, wherein the bond between amino acids at positions 182 and 189 is a disulfide bond.

8. (Amended) A peptide according to claim 1, wherein the amino acids at positions182 and 189 are selected from the group consisting of L-Cys, D-Cys, L-Pen and D-Pen.

9. (Amended) A peptide according to claim 16, wherein the amino acids at positions 183 and 186 are joined by a salt bridge, and are (X and Y) or (Y and X), respectively, where:

X is a positively charged amino acid, and

Y is a negatively charged amino acid.

10. A peptide according to claim 9, wherein X is selected from the group consisting of L- or D-Arg, Lys and Orn, and Y is selected from the group consisting of L- or D-Asp and Glu.

11. (Amended) A peptide according to claim 1, wherein the amino acids at positions 183 and 186 are joined by an amide covalent bond.

12. (Amended) A peptide according to claim 11, wherein the amino acids at positions 183 and 186 are (X and Y) or (Y and X), respectively, where:

X is selected from the group consisting of L- or D- Lys and Orn, and

Y is selected from the group consisting of L- or D- Asp and Glu.

Dwl B7

13. (Amended) A peptide of the sequence:

X^1m-Leu-Arg-Ile-Val-Gln-Cys-Arg -Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-X^2n

wherein X^1 and X^2 are each selected from the group consisting of L- or D- Arg, His, Lys and Tyr, and m and n are each 0, 1, 2 or 3 with the proviso that at least m or n is 1;

Dut B7

a cyclic disulfide thereof or an organic or inorganic acid addition salt thereof.

14. (Amended) A peptide of the sequence:

Y^1-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

wherein Y^1 is selected from the group consisting of the desamino form (H), acetyl (CH_3CO-) and other acyl groups;

a cyclic disulfide thereof or an organic or inorganic acid addition salt thereof.

15. (Amended) A peptide of the sequence:

Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-Y^2

wherein Y^2 is selected from the group of $CONH_2$ and alkyl amide groups;

a cyclic disulfide thereof or an organic or inorganic acid addition salt thereof.

16. (Amended) A peptide which is selected from the group consisting of:

Ref No.	STRUCTURE
9502	Leu Arg Ile Val Gln Pen Arg Ser Val Glu Gly Ser Pen Gly Phe
9405	CH_3CO- Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
9410	H - Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
9404	Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe - $CONH_2$
9407	Leu Arg Ile Val Gln Cys Lys Ser Val Glu Gly Ser Cys Gly Phe
9408	Leu Arg Ile Val Gln Cys Lys Ser Val Glu Gly Ser Cys Gly Phe (amide bond)
9604	Tyr Leu Arg Il Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe

9605	Lys Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
9618	Lys Lys Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
9607	Ala Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
9606	Leu Lys Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
9608	Leu Arg Ala Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
9403	Leu Arg Lys Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
9609	Leu Arg Ile Ala Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
9610	Leu Arg Ile Val Ala Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
9612	Leu Arg Ile Val Gln Cys Arg Ala Val Glu Gly Ser Cys Gly Phe
9613	Leu Arg Ile Val Gln Cys Arg Ser Ala Glu Gly Ser Cys Gly Phe
9615	Leu Arg Ile Val Gln Cys Arg Ser Val Glu Ala Ser Cys Gly Phe
9616	Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ala Cys Gly Phe
9602	Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Ala Phe
9501	Leu Arg Ile Val Gln Cys Arg Ser Val Glu D-Ala Ser Cys D-Ala Phe
9601	Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Ala

wherein the amino acid residue abbreviations used are in accordance with the standard peptide nomenclature:

Gly	=	Glycine;	Ile	=	Isoleucine;
Glu	=	Glutamic Acid;	Phe	=	Phenylalanine;
Cys	=	Cysteine;	Arg	=	Arginine;
Gln	=	Glutamine;	Leu	=	Leucine;
Ser	=	Serine;	Val	=	Valine;
Lys	=	Lysine;	Ala	=	Alanine;
Asp	=	Aspartic acid;	His	=	Histidine;

Orn = Ornithine; Tyr = Tyrosine;
Pen = Penicillamine (β,β'-Dimethyl-Cysteine).
wherein all amino acids, except for glycine, are of the L-absolute configuration, unless indicated as D-absolute configuration, and the peptide has a cyclic disulfide bond between Cys(182) and Cys(189) or Pen(182) and Pen(189) as appropriate,
or an organic or inorganic acid addition salt thereof.

17. (Amended) A method for the treatment of obesity in an animal, which comprises administering to the animal an effective amount of a peptide according to ~~any one of claims 1 or 7 to 16~~ claim 1.

18. A method according to claim 17, wherein the animal is a human.

19. (Cancelled).

20. (Cancelled).

21. (Cancelled).

22. (Cancelled).

23. (Cancelled).

24. (Cancelled).

25. (Cancelled).

26. (Cancelled).

PCT/AU98 00724
Received 05 July 1999

27. (Cancelled).

28. (Cancelled).

29. (Cancelled).

30. (Cancelled).

31. (Cancelled).

32. (Cancelled).

33. (Cancelled).

Sub C12 a

34. (Amended) A method according to claim 17 ~~or claim 18,~~ wherein the peptide is administered orally.

35. (Amended) Use of a peptide according to any one of claims 1 or 7 to 16 in the manufacture of a pharmaceutical composition for the treatment of obesity in an animal.

Sub C13 a

36. (Amended) A pharmaceutical composition for use in the treatment of obesity in an animal, which comprises an effective amount of a peptide according to Claim 1 ~~any one of claims 1 to 7 or 16~~, together with one or more pharmaceutically acceptable carriers and/or diluents.

add a1